UA110463C2 - ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я - Google Patents
ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'ЯInfo
- Publication number
- UA110463C2 UA110463C2 UAA201202214A UAA201202214A UA110463C2 UA 110463 C2 UA110463 C2 UA 110463C2 UA A201202214 A UAA201202214 A UA A201202214A UA A201202214 A UAA201202214 A UA A201202214A UA 110463 C2 UA110463 C2 UA 110463C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pharmaceutical composition
- methoxt
- benzazipine
- pyrimido
- methoxyphenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title 2
- 239000005711 Benzoic acid Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 235000010233 benzoic acid Nutrition 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001771 impaired effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23021209P | 2009-07-31 | 2009-07-31 | |
| PCT/US2010/002109 WO2011014248A1 (en) | 2009-07-31 | 2010-07-28 | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA110463C2 true UA110463C2 (ru) | 2016-01-12 |
Family
ID=42697590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201202214A UA110463C2 (ru) | 2009-07-31 | 2010-07-28 | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20110039826A1 (enExample) |
| EP (1) | EP2459173B1 (enExample) |
| JP (2) | JP2013500965A (enExample) |
| KR (1) | KR101762285B1 (enExample) |
| CN (2) | CN102548539A (enExample) |
| AR (1) | AR077436A1 (enExample) |
| AU (1) | AU2010276741B2 (enExample) |
| BR (1) | BR112012002265B8 (enExample) |
| CA (1) | CA2769531C (enExample) |
| CL (1) | CL2012000261A1 (enExample) |
| CO (1) | CO6612185A2 (enExample) |
| CR (1) | CR20120084A (enExample) |
| EA (1) | EA025277B1 (enExample) |
| EC (1) | ECSP12011703A (enExample) |
| GE (1) | GEP201606513B (enExample) |
| IL (1) | IL217839A (enExample) |
| IN (1) | IN2012DN01237A (enExample) |
| JO (1) | JO3434B1 (enExample) |
| MA (1) | MA33533B1 (enExample) |
| MX (2) | MX2012001196A (enExample) |
| MY (1) | MY174084A (enExample) |
| NZ (1) | NZ598096A (enExample) |
| PE (1) | PE20120788A1 (enExample) |
| SG (2) | SG10201404483VA (enExample) |
| TN (1) | TN2012000046A1 (enExample) |
| TW (1) | TWI522357B (enExample) |
| UA (1) | UA110463C2 (enExample) |
| UY (1) | UY32822A (enExample) |
| WO (1) | WO2011014248A1 (enExample) |
| ZA (1) | ZA201200944B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2299080T3 (es) * | 2004-05-14 | 2008-05-16 | Millennium Pharmaceuticals, Inc. | Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora. |
| WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| TWI392514B (zh) * | 2010-01-29 | 2013-04-11 | Colgate Palmolive Co | 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑 |
| US8653064B2 (en) | 2010-02-19 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
| UY34114A (es) | 2011-06-03 | 2013-01-03 | Millennium Pharm Inc | Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| US9724354B2 (en) | 2013-03-22 | 2017-08-08 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase |
| EP3076963A4 (en) | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
| JP2018524292A (ja) | 2015-07-21 | 2018-08-30 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラキナーゼインヒビターと化学療法剤の投与 |
| USD797120S1 (en) | 2015-08-28 | 2017-09-12 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with graphical user interface |
| WO2025075211A1 (en) | 2023-10-03 | 2025-04-10 | Takeda Pharmaceutical Company Limited | Alisertib and paclitaxel for treating small cell lung cancer |
| WO2025245045A1 (en) | 2024-05-21 | 2025-11-27 | The Regents Of The University Of California | Methods of treating lung cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747487A (en) * | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| JP2001507349A (ja) | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用 |
| WO2001010462A1 (en) | 1999-08-11 | 2001-02-15 | Idec Pharmaceuticals Corporation | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
| EP1315484A1 (en) * | 2000-03-24 | 2003-06-04 | Baker Norton Pharmaceuticals, Inc. | Taxane-based compositions and methods of use |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| ES2299080T3 (es) * | 2004-05-14 | 2008-05-16 | Millennium Pharmaceuticals, Inc. | Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora. |
| US20070104785A1 (en) * | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
| SI1962830T1 (sl) * | 2005-12-23 | 2013-07-31 | Glaxosmithkline Llc | Azaindolni inhibitorji kinaz Aurora |
| MX2009000132A (es) | 2006-06-30 | 2009-01-26 | Schering Corp | Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53. |
| DK2046292T3 (da) * | 2006-07-21 | 2010-06-07 | Novartis Ag | Formuleringer for benzimidazolylpyridylethere |
| EP2054413A2 (en) | 2006-08-09 | 2009-05-06 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090203671A1 (en) * | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| WO2010074724A1 (en) * | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| US8653064B2 (en) * | 2010-02-19 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
-
2010
- 2010-07-26 JO JOP/2010/0264A patent/JO3434B1/ar active
- 2010-07-28 SG SG10201404483VA patent/SG10201404483VA/en unknown
- 2010-07-28 JP JP2012522810A patent/JP2013500965A/ja active Pending
- 2010-07-28 BR BR112012002265A patent/BR112012002265B8/pt active IP Right Grant
- 2010-07-28 WO PCT/US2010/002109 patent/WO2011014248A1/en not_active Ceased
- 2010-07-28 KR KR1020127004651A patent/KR101762285B1/ko active Active
- 2010-07-28 GE GEAP201012599A patent/GEP201606513B/en unknown
- 2010-07-28 SG SG2012005401A patent/SG177751A1/en unknown
- 2010-07-28 AU AU2010276741A patent/AU2010276741B2/en active Active
- 2010-07-28 CN CN2010800415230A patent/CN102548539A/zh active Pending
- 2010-07-28 CN CN201410112836.0A patent/CN103893186B/zh active Active
- 2010-07-28 NZ NZ59809610A patent/NZ598096A/en unknown
- 2010-07-28 US US12/844,920 patent/US20110039826A1/en not_active Abandoned
- 2010-07-28 MY MYPI2012000438A patent/MY174084A/en unknown
- 2010-07-28 UA UAA201202214A patent/UA110463C2/ru unknown
- 2010-07-28 MX MX2012001196A patent/MX2012001196A/es not_active Application Discontinuation
- 2010-07-28 MX MX2015002869A patent/MX348197B/es unknown
- 2010-07-28 EA EA201270205A patent/EA025277B1/ru unknown
- 2010-07-28 CA CA2769531A patent/CA2769531C/en active Active
- 2010-07-28 PE PE2012000132A patent/PE20120788A1/es not_active Application Discontinuation
- 2010-07-28 EP EP10739413.2A patent/EP2459173B1/en active Active
- 2010-07-28 IN IN1237DEN2012 patent/IN2012DN01237A/en unknown
- 2010-07-30 TW TW099125531A patent/TWI522357B/zh active
- 2010-07-30 AR ARP100102812 patent/AR077436A1/es not_active Application Discontinuation
- 2010-08-02 UY UY32822A patent/UY32822A/es not_active Application Discontinuation
-
2012
- 2012-01-27 TN TNP2012000046A patent/TN2012000046A1/en unknown
- 2012-01-30 IL IL217839A patent/IL217839A/en active IP Right Grant
- 2012-01-31 CL CL2012000261A patent/CL2012000261A1/es unknown
- 2012-02-08 ZA ZA2012/00944A patent/ZA201200944B/en unknown
- 2012-02-09 CO CO12022583A patent/CO6612185A2/es not_active Application Discontinuation
- 2012-02-16 MA MA34640A patent/MA33533B1/fr unknown
- 2012-02-17 CR CR20120084A patent/CR20120084A/es unknown
- 2012-02-29 EC ECSP12011703 patent/ECSP12011703A/es unknown
-
2013
- 2013-06-11 US US13/914,705 patent/US9127011B2/en active Active
-
2015
- 2015-02-05 JP JP2015021023A patent/JP6014695B2/ja active Active
- 2015-08-28 US US14/838,878 patent/US9504693B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA110463C2 (ru) | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я | |
| UY26139A1 (es) | Composiciones de medicamentos a base de compuestos anticolinérgicamente activos y beta- miméticos | |
| EA201101243A1 (ru) | 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
| WO2007127635A3 (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
| ECSP034571A (es) | Nuevas composiciones de medicamentos a base de sales de tiotropio y sales del salmeterol | |
| MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| WO2008154083A3 (en) | Compounds, compositions and methods for the treatment of synucleinopathies | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| UY27627A1 (es) | Aza - arilpiperazinas | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| ATE302774T1 (de) | Arzneimittel enthaltend betamimetika und ein neues anticholinergikum | |
| BRPI0411098A (pt) | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos | |
| UY27759A1 (es) | Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico. | |
| MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
| ATE443722T1 (de) | Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| ECSP045355A (es) | Medicamento que contiene esteroides y un nuevo anticolinérgico | |
| ATE466574T1 (de) | Verfahren und zusammensetzungen zur oralen fts- abgabe |